HC Wainwright & Co. Initiates Coverage On Odyssey Therapeutics with Buy Rating, Announces Price Target of $44

Benzinga Newsdesk www.benzinga.com Neutral 72.5%

Neg 0% Neu 72.5% Pos 0%

HC Wainwright & Co. analyst Emily Bodnar initiates coverage on Odyssey Therapeutics (NASDAQ:ODTX) with a Buy rating and announces Price Target of $44.